| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1018729941 |
| P356 | DOI | 10.1038/ONC.2012.369 |
| P698 | PubMed publication ID | 22926520 |
| P50 | author | Richard Moriggl | Q38327183 |
| P2093 | author name string | P Ziegler | |
| G Müller-Newen | |||
| E Jost | |||
| N Chatain | |||
| D Fahrenkamp | |||
| H Schmitz-Van de Leur | |||
| P2860 | cites work | STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells | Q24534351 |
| The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains | Q28210453 | ||
| Structure, function, and regulation of STAT proteins | Q28282800 | ||
| Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis | Q28288381 | ||
| Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation | Q29617586 | ||
| Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity | Q30159676 | ||
| The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. | Q30165112 | ||
| Gab2 promotes hematopoietic stem cell maintenance and self-renewal synergistically with STAT5 | Q33531794 | ||
| Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation | Q33874580 | ||
| Mutational switch of an IL-6 response to an interferon-gamma-like response | Q34031049 | ||
| Novel dual Src/Abl inhibitors for hematologic and solid malignancies | Q34121339 | ||
| Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib | Q34210528 | ||
| Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. | Q35885308 | ||
| Src kinases as targets for B cell acute lymphoblastic leukaemia therapy | Q36150854 | ||
| Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl | Q36365946 | ||
| Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B | Q36672274 | ||
| STAT5 signaling in normal and pathologic hematopoiesis | Q36813606 | ||
| Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. | Q37462729 | ||
| The role of STAT5 in the development, function, and transformation of B and T lymphocytes. | Q37833131 | ||
| Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway | Q38295577 | ||
| The role of the N-terminal domain in dimerization and nucleocytoplasmic shuttling of latent STAT3. | Q39591458 | ||
| Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin | Q39695105 | ||
| Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality | Q39885657 | ||
| Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates | Q40039203 | ||
| Tyrosine-phosphorylated STAT5 accumulates on podosomes in Hck-transformed fibroblasts and chronic myeloid leukemia cells | Q40132820 | ||
| Activated STAT5 proteins induce activation of the PI 3-kinase/Akt and Ras/MAPK pathways via the Gab2 scaffolding adapter | Q40434680 | ||
| The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases | Q40684182 | ||
| The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway | Q40937408 | ||
| Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein | Q41326706 | ||
| Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia | Q42089534 | ||
| Cytoplasmic localization of phosphorylated STAT5 in human acute myeloid leukemia is inversely correlated with Flt3-ITD | Q42349451 | ||
| Nucleocytoplasmic shuttling of persistently activated STAT3. | Q42825173 | ||
| Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes | Q43255631 | ||
| Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases | Q44189751 | ||
| Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia | Q44851706 | ||
| KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. | Q45960933 | ||
| Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction | Q46937459 | ||
| Mouse Models for Human Hemato-Lymphopoiesis | Q57201683 | ||
| Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias | Q58029666 | ||
| Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A | Q78069715 | ||
| Structural basis for selective inhibition of Src family kinases by PP1 | Q78192599 | ||
| Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT) | Q80458378 | ||
| Transcriptome analysis and tumor suppressor requirements of STAT5-induced senescence | Q84382696 | ||
| P433 | issue | 31 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3587-3597 | |
| P577 | publication date | 2012-08-27 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells | |
| P478 | volume | 32 |
| Q28538914 | BCR-ABL affects STAT5A and STAT5B differentially |
| Q38193659 | Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy |
| Q40484034 | Effects of a Particular Heptapeptide on the IFN-α-Sensitive CML Cells |
| Q34781322 | Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia |
| Q36140620 | Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells. |
| Q37589123 | Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus |
| Q27004027 | Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia |
| Q37536748 | MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling |
| Q46679237 | NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells |
| Q28302461 | PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis |
| Q92814428 | Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers |
| Q26861574 | Protein tyrosine phosphatases as wardens of STAT signaling |
| Q38177821 | STAT5 acetylation: Mechanisms and consequences for immunological control and leukemogenesis |
| Q91727931 | Signal transducer and activator of transcription (STAT)-5: an opportunity for drug development in oncohematology |
| Q38217719 | Src family kinases and their role in hematological malignancies |
| Q41849009 | Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction |
| Q42657514 | Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells. |
Search more.